Sansure Biotech Inc.

Equities

688289

CNE1000043J1

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
18.8 ^CNY	+0.53%		+2.56%	-3.84%

Feb. 29	Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84%	MT
Feb. 28	Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Singlera Genomics Inc. announced that it has received CNY 300 million in funding from Wuxi Guojing Investment Management Co., Ltd., Galaxy Yuanhui Investment Co., Ltd., Shanghai Junci Investment Management Co., Ltd., Sansure Biotech Inc., Qiandao Investment Fund Management Co., Ltd.

June 07, 2022

Singlera Genomics Inc. has received CNY 300 million in series B+ funding led by Forstone Capital on June 8, 2022. The transaction included participation from other investors, Wuxi Guojing Investment Management Co., Ltd., Galaxy Yuanhui Investment Co., Ltd., Shanghai Junci Investment Management Co., Ltd., Sansure Biotech Inc., Qiandao Investment Fund Management (Beijing) Co., Ltd. and Unifortune Investment.

Latest news about Sansure Biotech Inc.

Sansure Biotech's 2023 Profit Drops 81% as Revenue Slumps 84%	Feb. 29	MT
Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
ASEP Medical Holdings Signs JV Agreement with Chinese Medical Diagnostics Co Sansure Biotech Inc.	Nov. 22	MT
Sansure Biotech Secures EU Certification For In Vitro Diagnostic Device	Nov. 15	MT
Sansure Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-10-10	CI
Sansure Biotech Inc.'s Equity Buyback announced on October 21, 2022, has closed with 9,865,793 shares, representing 1.7% for CNY 200 million.	23-10-08	CI
Sansure Biotech Gets EU CE certification for 60 products	23-09-22	MT
Certain A Shares of Sansure Biotech Inc. are subject to a Lock-Up Agreement Ending on 28-AUG-2023.	23-08-27	CI
Sansure Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Sansure Biotech's Human Papillomavirus Kit Gets EU Registration Certificate	23-07-27	MT
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-06-30	CI
Sansure Biotech Inc.(SHSE:688289) dropped from Shanghai Stock Exchange Health Care Sector Index	23-06-09	CI
Sansure Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-04-04	CI
Sansure Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Asep Inc. Lower After Signing JV Term Sheet with Leading Chinese Medical Diagnostic Co. Sansure Biotech Inc.	23-01-30	MT
Sansure Biotech Gets Certification for COVID-19 Kit	23-01-30	MT
ASEP Medical Holdings Inc. Signs Joint Venture Term Sheet with Sansure Biotech Inc. in Preparation for the Commercialization of the Sepset(ER) Sepsis Diagnostic Test in China	23-01-27	CI
Tranche Update on Sansure Biotech Inc.'s Equity Buyback Plan announced on October 21, 2022.	23-01-02	CI
Sansure Biotech to Repurchase Up to $28 Million Shares	22-10-21	MT
Sansure Biotech Inc. announces an Equity Buyback for CNY 200 million worth of its shares.	22-10-20	CI
Sansure Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-20	CI
Sansure Biotech Inc. authorizes a Buyback Plan.	22-10-19	CI
Sansure Biotech Inc.(XSSC:688289) added to S&P Global BMI Index	22-09-19	CI

Chart Sansure Biotech Inc.

Duration

Period

More charts

Company Profile

Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-26 - Q4 2023 Earnings Release

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
SANSURE BIOTECH INC.	-3.84%	1.48B
BIOMÉRIEUX	+1.09%	12.59B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-12.53%	7.42B
DIASORIN S.P.A.	+2.15%	5.35B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.37%	4.51B
LANTHEUS HOLDINGS, INC.	+5.94%	4.47B
10X GENOMICS, INC.	-50.82%	3.21B
ANDON HEALTH CO., LTD.	+11.34%	2.71B
VITROLIFE AB	-16.49%	1.96B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.07%	1.73B

Diagnostic & Testing Substances

Sansure Biotech Inc.

Equities

688289

CNE1000043J1

Medical Equipment, Supplies & Distribution

Singlera Genomics Inc. announced that it has received CNY 300 million in funding from Wuxi Guojing Investment Management Co., Ltd., Galaxy Yuanhui Investment Co., Ltd., Shanghai Junci Investment Management Co., Ltd., Sansure Biotech Inc., Qiandao Investment Fund Management Co., Ltd.

Latest news about Sansure Biotech Inc.

Chart Sansure Biotech Inc.

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Diagnostic & Testing Substances